Molecular Imaging: Page 16

New theranostics delivery route tested for prostate cancer

A new delivery route for theranostic agents via arteries rather than intravenous injections could dramatically increase their effects on tumors in patients with prostate cancer.

August 13, 2024

Dynamic PET/CT and pathologic images for a 66-year-old male participant. (A) Axial dynamic PET/CT image acquired during intravenous administration of Ga-68 PSMA-11 demonstrates the hypermetabolic primary prostatic tumor. The right-sided portion of the lesion used for volume of interest (VOI) analysis is outlined in pink, reflecting the margins seen on a prior T2-weighted MRI scan. Tumor radiotracer uptake extends across midline into the left anterior apex (*). (B) Axial dynamic PET/CT image acquired during selective right prostatic arterial administration of Ga-68 PSMA-11 demonstrates intense radiotracer uptake in the VOI outlined in pink. There is comparatively minimal uptake in the unperfused left-sided portion of the tumor (*). The arterial sheath and catheters in the right groin are partially visualized (arrow). (C) Photomicrograph (hematoxylin-eosin stain; unmagnified) of the prostatic apex after radical prostatectomy. The midline (dotted line) and dominant tumor margins (solid line) are shown. Small additional areas of carcinoma (■) without T2-weighted MRI correlates were also identified at pathologic examination.

SPECT/CT improves management of Pluvicto patients

SPECT/CT imaging can help manage patients undergoing radiopharmaceutical therapy with Pluvicto for advanced prostate cancer.

August 12, 2024

Spect Pluvicto Response Thumbnail

PET can predict MACE in cardiac sarcoidosis patients

PET imaging can help identify whether cardiac sarcoidosis patients are at higher risk of major adverse cardiac events (MACE).

August 9, 2024

A graphical abstract of the study. Image courtesy of JACC: Cardiovascular Imaging.

PET tracer performs well in prostate cancer trial

An experimental PET radiotracer that targets gastrin-releasing peptide receptors (GRPR) on prostate cancer cells has shown promise in a phase II clinical trial in Australia.

August 8, 2024

Fused PET/CT, maximum-intensity projection PET, and lung-windowed CT images (from left to right) from Cu-64 SAR-BBN (top row) and Ga-68 PSMA-11 (bottom row) PET/CT study of patient demonstrating left subpleural lesion (arrows, SUVmax of 10 at 1 hour) that showed Cu-64 SAR-BBN uptake but no Ga-68 PSMA-11 uptake. PSA was 1.84 ng/mL at time of imaging. This patient underwent lobectomy, with histopathology demonstrating metastatic prostate cancer.

Study explores neurologic problems in Pluvicto patients

Men treated with Lu-177 PSMA-617 for prostate cancer may experience neurologic problems after starting therapy, but most are mild and manageable through conservative methods.

August 2, 2024

A graphical abstract of the study.

New theranostics pairing tested in breast cancer patients

By Kate Madden Yee

A new theranostics pairing of molecular imaging and radioligand therapy shows promise as a treatment option for patients with metastatic breast cancer, researchers have found.

July 31, 2024

FES-PET effective for staging breast cancer in phase II trial

F-18 fluroestradiol (FES)-PET/CT appears as effective as standard imaging for staging women with estrogen receptor-positive locally advanced breast cancer or evaluating suspected recurrence.

July 26, 2024

The patient was a woman in her 50s with suspected recurrence of invasive lobular breast cancer. A, maximum intensity projection image from FDG-PET/CT demonstrating avid foci in the chest (red arrow). Transaxial CT (B) and transaxial fused FDG-PET/CT image (C) showing that the chest avidity corresponds to FDG-avid lung nodules (red arrows) suspicious for malignancy. The lung nodule was subsequently biopsied but found to represent benign granulomatous inflammation and thus a false positive on FDG-PET/CT. D, maximum intensity projection image from FES-PET/CT demonstrating multifocal uptake suspicious for malignancy. E, transaxial CT and fused FES-PET/CT demonstrating no FES-avidity in the biopsy proven benign granulomatous lung nodules (red arrows), thus true negative on FES-PET/CT. FES-avidity in nodes (white arrow) is suspicious for malignancy. F, transaxial CT and fused FES-PET/CT demonstrates gastric avidity (blue arrow) suspicious for malignancy. G, transaxial CT and fused FES PET/CT demonstrates FES-avid osseous foci (yellow arrow) suspicious for malignancy. This osseous focus was subsequently biopsied and proved to be an osseous metastasis and thus true positive on FES-PET/CT.

PET/MRI rules out tau protein in late-life depression

A PET/MRI study has provided insights into the neurobiology of late-life depression, finding tau protein is not involved in the condition.

July 25, 2024

Coronal and axial slice of the average cortical F-18 MK-6240 SUVR [standard uptake value ratio] image for each study population. SUVR images were corrected for partial volume effects and masked with the gray matter mask used for volume of interest delineation. Overall tau accumulation is comparable between the late-life depression (LLD, middle column) and non-depressed cognitively unimpaired comparison (HC, left column) groups, while abnormal tau accumulation, which is most pronounced in the mesial temporal lobe, can be seen in the mild cognitive impairment due to Alzheimer's disease group (right column). Image and caption courtesy of the American Journal of Geriatric Psychiatry.

Tau PET identifies grey matter atrophy in retired athletes

Flortaucipir PET imaging is able to identify neuropathological brain changes in retired contact sport athletes at risk of neurodegeneration.

July 24, 2024

Example of the flortaucipir tau-PET signal and distribution of low grey matter volume in a single former athlete. Spatial maps of the flortaucipir tau-PET standardized update value (SUVR) (top) and the reduced grey matter volumes showed in blue and defined as voxels with a w-score of >1.5 below the mean (bottom) in a single former athlete. Image courtesy of the Journal of Neurology.

PET/MRI superior to PET/CT in cancer patients

FDG-PET/MRI is comparable or superior in diagnostic performance to FDG-PET/CT across a range of cancers and endpoints.

July 18, 2024

FAPI-SPECT reveals damage to myocardium after heart attack

Technetium-99m (Tc-99m) FAPI-SPECT shows promise as a tool for assessing cellular and structural changes in the myocardium after heart attack.

July 16, 2024

Emergency percutaneous coronary intervention images, Tc-99m MIBI perfusion images and Tc-99m FAPI images of STEMI patients. In STEMI patients, there is a localized yet inhomogeneous uptake of Tc-99m FAPI. Notably, the extent of Tc-99m FAPI uptake significantly surpasses the area of perfusion defects. Despite similarities in coronary artery lesions (culprit vessels identified as the left anterior descending artery in image A and the right coronary artery in image B, white arrows), and comparable myocardial perfusion impairment, patients with larger Tc-99m FAPI uptake areas exhibit ventricular remodeling. Image courtesy of the Journal of Nuclear Cardiology.

Bone marrow disorders associated with SARs in Lutathera patients

Pretreatment bone marrow disorders may predict which patients are at risk for severe adverse reactions (SARs) when treated with lutetium-177 DOTATATE.

July 15, 2024

2024 07 11 Sa Rs Patients Lu 177 Dotatate Voter

Page 16 of 610